Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/news/2011-10-04/merck-kgaa-ono-pharmaceutical-to-develop-oral-drug-for-ms.html

Bloomberg News

Merck KGaA, Ono Pharmaceutical to Develop Oral Drug for MS

October 04, 2011

(Adds Novartis’ competing pill in third paragraph)

Oct. 4 (Bloomberg) -- Merck KGaA said its Merck Serono unit will develop and market a pill for multiple sclerosis with Japan’s Ono Pharmaceutical Co. to compete with a similar product made by Novartis AG.

The experimental therapy, ONO-4641, is in the second of three stages of clinical trials usually required for regulatory approval, Merck said in a statement today. The companies will also collaborate in Japan on the development and marketing of Merck’s Stimuvax, a cancer treatment in the final stage of trials, according to the statement.

ONO-4641 is Darmstadt, Germany-based Merck’s second attempt to develop a tablet for MS after it decided not to seek approval of its cladribine pill in June. Novartis’s Gilenya, the first oral drug for MS, was approved last year and Israel’s Teva Pharmaceutical Industries Ltd. is developing a competing laquinimod pill.

“There’s a huge unmet clinical need,” said Gustav Ando, a London-based analyst at consulting company IHS Global Insight. With a pill, “the patient doesn’t have to go to the hospital for monthly injections, which significantly impedes quality of life.”

Novartis has 13,000 patients on Gilenya, the Basel, Switzerland-based company said in July. The drug may reach $1.2 billion in sales by 2013 and $2.1 billion by 2015, according to analysts’ estimates compiled by Bloomberg.

“It’s a very lucrative market,” Ando said.

--Editors: Kristen Hallam, David Risser

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus